Why Ultra-Precision Logistics is the Decisive Factor in CGT Success

With increasingly successful marketing authorizations around the globe, we are witnessing an acceleration in the evolution of cell and gene therapies (CGT). In this landscape, the product is not a synthetic chemical or a standard biologic; it encompasses living cells (autologous or allogeneic), genetic material delivered in vivo, or genetically engineered cellular constructs—each functioning as dynamic therapeutic agents with curative potential.

This manufacturing-to-patient continuum is arguably one of the more complex workflows in modern medicine. Having spent years observing the friction points in clinical delivery, the CGT R&D industry has realized that even the most brilliant scientific breakthrough becomes critically compromised in the absence of robust operations including logistics management. Its success does not just depend on the lab—it lives or dies by the timeliness and specificity of cold-chain logistics, quality assurance systems, and operational infrastructures that enable it.

The Accelerating CGT Landscape: Growth and Enablement

The momentum in this field is hard to deny. In 2024, the FDA hit a milestone by approving a record number of CGTs for marketing authorization, including landmarks like Tecelra for solid tumors and Amtagvi (the first TIL therapy). As we move through 2026 with over 40 approved therapies globally¹⁾, CGT is increasingly transiting from experimental to commercial reality.

This momentum is reflected in unprecedented market expansion (Figure 1). The global CGT clinical trials market, valued at 11.59 billion USD in 2024, is projected to reach 47.40 billion USD by 2033, representing a CAGR of 16.9%²⁾. This nearly four-fold increase over the next decade underscores the scale of investment and the growing confidence in CGT as a transformative therapeutic modality.

Figure 1: Global Cell and Gene Therapy Clinical Trials Market Size, 2024-2033 (USD Billion)

What's most striking is the parallel acceleration of CGT development across global regions. The Asia-Pacific (APAC) region, spearheaded by China, South Korea, and Japan, has become a significant contributor to the global CGT landscape, alongside established hubs in North America. China represents a substantial and growing proportion of global CGT trials, with some estimates suggesting over 30% of trial volume³⁾. In as much, this geographic expansion is broadening the foundation for CGT innovation. With this scientific momentum, sophisticated logistics management has emerged as a key enabler to both academic and community sites alike, serving as the operational backbone that ensures these life-saving therapies maintain their integrity across increasingly global supply chains with increasing risks for global disruption.

The Critical Role of Logistics in CGT Delivery

There is a common misconception that as technology matures, logistics get easier. In CGT, the reality is quite different: as therapies become more sophisticated, the supply chain becomes exponentially more complex—and exponentially more critical. Unlike traditional clinical trials involving linear, one-way distribution of stable products, CGT mandates a fundamental operational shift:

• Product Irreplaceability: Autologous CGT products are patient-specific and irreplaceable—product loss directly eliminates that patient's treatment option. Allogeneic products, while not patient-specific, involve high manufacturing costs and extended production timelines, making any loss clinically and financially significant.
• Stringent Temperature and Time Requirements: CGT products have strict storage requirements. Cell therapies typically require cryogenic storage below -150°C, while gene therapies may require ultra-cold storage (-80°C to -60°C) or refrigeration (2°C to 8°C) depending on formulation. Temperature deviations can trigger irreversible cellular damage (apoptosis) in cell therapies or viral vector degradation and loss of transduction efficiency in gene therapies, transforming a potentially curative therapy into clinical failure.
• Operational Redundancy as Standard Practice: The greatest logistical risk is time. Reliance on a single-route strategy is operationally untenable. To mitigate risks from flight cancellations or customs delays, contingency protocols must be pre-established, including multi-modal transport options, specialized ground fleets, private charters, and when necessary, expedited final delivery.
• Strategic Investment in Logistics Infrastructure: Specialized CGT logistics can account for up to 25% of development costs⁴⁾. However, this should not be viewed as overhead, as it is a fundamental investment in product integrity, clinical outcomes, and patient safety.

Strategic Imperatives: Redesigning Trials for the APAC Reality

To succeed in 2026 and beyond and with increasingly geopolitical boundary disruptions and challenges, logistics must be recognized as a strategic enabler, not a back-end service. Integrating logistics as a foundational pillar of trial design from the outset is essential for CGT success and possibly patient survival. This is particularly important in APAC, where the diverse and evolving landscape presents unique opportunities for innovation in trial execution.

• Navigating Regulatory Fragmentation: While North America operates under a unified FDA framework, APAC presents multiple regulatory jurisdictions including China's NMPA, Korea's MFDS, and Japan's PMDA. Successful APAC logistics requires integrated regulatory compliance management—ensuring that all cross-border documentation for human biological materials is pre-cleared, validated, and audit-ready to prevent customs delays that can compromise product viability.
• The Cold Chain as a "Stability Guardian": APAC's climatic diversity, from tropical heat in Southeast Asia to temperate conditions in Northeast Asia, CGT supply chains require more than conventional temperature-controlled packaging. Furthermore, with climate-validated thermal packaging and real-time monitoring systems, this necessitates contingency planning to overcome infrastructure gaps at regional airports, with many lacking pharmaceutical-grade cold storage, as well as partnerships with specialized logistics providers experienced in biological materials transport.
• Logistics-Driven Site Selection: A site's recruitment potential is insufficient if they lack the necessary cold chain infrastructure. Site selection must consider access to cryogenic storage (liquid nitrogen for < -150°C), ultra-cold freezers (-80°C), and controlled refrigeration (2-8°C), as well as proximity to cargo hubs with specialized CGT transport capabilities. In APAC, logistical connectivity is as critical as clinical expertise and is increasing in complexity, not just in the specific requirements of the trafficked CGT but also in the sheer volume of these assets that are being moved great distances typically in less than 24 hours

Conclusion: From Scientific Precision to Delivery Precision

The APAC CGT market is projected to expand significantly through 2034. However, the winners in this space will not be those with just the best science, but those with the most resilient infrastructure in the logistics and cold chain supply.

For the leaders in CGT industry, it is essential to ensure that the precision achieved in the lab is not lost in the supply chain. By elevating logistics from a supportive role to a foundational pillar of trial strategy and design, we may be able to better fulfill our ultimate goal: ensuring that the potential of a cell and gene therapy safely reaches patients who have run out of other options, no matter where they may live. In 2026 and beyond, the "Last Mile" is no longer a distance; it is the ultimate measure of our clinical and operational excellence.

References

• Approved Cellular and Gene Therapy Products | FDA
• Precedence Research. (2024, September 11). Cell and gene therapy clinical trials market size to hit USD 47.40 bn by 2033 [Press release]. https://www.biospace.com/press-releases/cell-and-gene-therapy-clinical-trials-market-size-to-hit-usd-47-40-bn-by-2033
• Alliance for Regenerative Medicine. (2024). "Annual Report: Cell and Gene Therapy Clinical Trials Landscape."
• Intuition Labs. (2026, March 16) "Cell & Gene Therapy Logistics & Supply Chain." https://intuitionlabs.ai/articles/cell-gene-therapy-logistics-supply-chain

Nayoung Lee

Vice President, Commercial, APAC, Parexel